Ukraine has secured 12,000 doses of the medication PLX-R18, intended for treating radiation sickness (acute radiation syndrome), from the Israeli biotechnology firm Pluri. This purchase is part of the country's preparedness for potential nuclear threats.

This information was shared by Israel's ambassador to Ukraine, Michael Brodsky, on Telegram, referencing The Times of Israel.

Stockpiling for Nuclear Threat: Ukraine Acquires PLX-R18 Medication

The ambassador quoted the Israeli publication, stating that "the Israeli company Pluri has signed a contract with a Ukrainian cord blood bank for the supply of PLX-R18 medication." This medication aids in the recovery of platelets as well as red and white blood cells damaged by radiation exposure.

Overall, Ukraine will receive sufficient doses to treat 6,000 individuals. The purchased medication will be stored as a reserve in case of a nuclear threat, and if necessary, it will be rapidly dispatched to hospitals across the country to assist those affected.

In March, Russian forces used chemical weapons against the Armed Forces of Ukraine nearly 770 times.

Earlier, the General Staff of the Armed Forces of Ukraine reported 767 instances of Russian military using munitions containing hazardous chemical substances against Ukraine's defense forces throughout March 2025.

Since February 2023, when such attacks became systematic, a total of 7,730 similar incidents have been recorded.

As of early March, since the onset of the full-scale invasion of Ukraine, Russian troops have used munitions with toxic chemical compounds more than 6,900 times.

In March 2024, Ukraine's delegation at the OSCE called on the international community to respond, not just with political condemnation, to Russia's use of chemical weapons against Ukrainian defenders.